ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease (ParkinStim)

March 9, 2015 updated by: Great Lakes NeuroTechnologies Inc.

ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I

The purpose of this study is to evaluate the effects of transcranial direct current stimulation (tDCS) on patients with Parkinson's disease during sleep.

Study Overview

Status

Completed

Conditions

Detailed Description

The clinical study will follow a counterbalanced crossover design during which subjects will undergo two separate pairs of two-consecutive-overnight sleep studies and receive anodal tDCS (active or sham) to M1. The first sleep study in each pair will acclimate subjects to the sleep laboratory and minimize "first night" effects, thus no tDCS will be applied. The second sleep study in each pair will include active or sham tDCS, presented in a pseudorandom order such that approximately half of the subjects receive active tDCS first while the other half receives sham first. The two pairs of sleep studies will be separated by one to three weeks.

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60612
        • Rush University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

38 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of idiopathic Parkinson's disease (PD) according to the UK PD brain bank criteria
  • Hoehn and Yahr stage II-III when off anti-parkinsonian medication
  • Able to provide informed consent
  • Currently taking levodopa (300-800 mg per day)
  • On stable regimen of anti-parkinsonian medication for at least one month before study entry and able to continue on a stable regimen for the duration of the study
  • Presence of early morning akinesia
  • Naïve to tDCS.

Exclusion Criteria:

  • Children will be excluded from this study due to the fact that they are unlikely to have PD
  • Significant medical or psychiatric illness, significant neurological disease other than PD, metal objects and/or deep brain stimulators in the head that might pose a hazard during tDCS
  • Dementia, as evidenced by a score less than 26 on the Montreal Cognitive Assessment
  • Significant depression (Geriatric Depression Scale score < 20)
  • Presence of hallucinations
  • Having undergone any surgical procedure for treatment of PD including deep brain stimulation (DBS), pallidotomy, thalamotomy, or other brain surgeries
  • A history of seizures
  • A known history of severe sleep apnea or sleep onset insomnia
  • Skin diseases that could potentially cause irritations under electrodes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active tDCS
Receives 20 minutes of anodal tDCS three times while sleeping during the night.
Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
Sham Comparator: Sham tDCS
Receives 20 minutes of sham tDCS three times while sleeping during the night.
Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PD motor scores measured by Kinesia HomeView
Time Frame: Average change from two days before tDCS sleep study to two days after tDCS sleep study
PD motor symptoms will be assessed for two days before (baseline) and two days after each tDCS sleep study using Kinesia HomeView. Changes for active tDCS will be compared to changes for sham tDCS.
Average change from two days before tDCS sleep study to two days after tDCS sleep study

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleepiness
Time Frame: Average change from two days before tDCS sleep study to two days after tDCS sleep study
Epworth Sleepiness Scale
Average change from two days before tDCS sleep study to two days after tDCS sleep study
tDCS sensations
Time Frame: Day after tDCS sleep studies
Each subject will complete a questionnaire regarding sensations they felt during the night the day after each tDCS sleep study.
Day after tDCS sleep studies
Motor scores measured by the Unified Parkinson's Disease Rating Scale
Time Frame: Average change from day before tDCS sleep study to day after tDCS sleep study
Average change from day before tDCS sleep study to day after tDCS sleep study
Overnight Polysomnography
Time Frame: During each sleep study
Polysomnography parameters will be compared during the active and sham tDCS sleep studies.
During each sleep study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dustin A Heldman, Ph.D., Great Lakes NeuroTechnologies

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2014

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

April 25, 2014

First Submitted That Met QC Criteria

April 25, 2014

First Posted (Estimate)

April 29, 2014

Study Record Updates

Last Update Posted (Estimate)

March 10, 2015

Last Update Submitted That Met QC Criteria

March 9, 2015

Last Verified

March 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease

Clinical Trials on Active tDCS

3
Subscribe